Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74695923 | 7469592 | 3 | F | 20100503 | 20160823 | 20100713 | 20160914 | EXP | US-ROCHE-714037 | ROCHE | 81.25 | YR | F | Y | 56.10000 | KG | 20160914 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74695923 | 7469592 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | FREQUENCY: OVER 30-90 MINUTES ON DAYS 1 AND 15. CYCLE= 28 DAYS. COURSE NO: 1 | U | 125085 | 1159 | MG | SOLUTION FOR INFUSION | ||||||
| 74695923 | 7469592 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 28 DAYS,FREQUENCY OVER 30-90MIN ON DAYS 1 AND 15,LAST DOSE PRIOR TO SAE 26 APRIL 2010,COURSE 3 | U | 125085 | 10 | MG/KG | |||||||
| 74695923 | 7469592 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | FREQUENCY: OVER 30-90 MINUTES ON DAYS 1 AND 15. CYCLE= 28 DAYS. COURSE NO: 1 | U | 125085 | 1114 | MG | SOLUTION FOR INFUSION | ||||||
| 74695923 | 7469592 | 4 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | FREQUENCY: OVER 30-90 MINUTES ON DAYS 1 AND 15. CYCLE= 28 DAYS. COURSE NO: 1 | U | 125085 | 1122 | MG | SOLUTION FOR INFUSION | ||||||
| 74695923 | 7469592 | 5 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | FREQUENCY: OVER 30-90 MINUTES ON DAYS 1 AND 15. CYCLE= 28 DAYS. COURSE NO: 1 | U | 125085 | 1122 | MG | SOLUTION FOR INFUSION | ||||||
| 74695923 | 7469592 | 6 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | FREQUENCY: OVER 30-90 MINUTES ON DAYS 1 AND 15. CYCLE= 28 DAYS. COURSE NO: 1 | U | 125085 | 1122 | MG | SOLUTION FOR INFUSION | ||||||
| 74695923 | 7469592 | 7 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | FREQUENCY: OVER 30-90 MINUTES ON DAYS 1 AND 15. CYCLE= 28 DAYS. COURSE NO: 1 | U | 125085 | 1122 | MG | SOLUTION FOR INFUSION | ||||||
| 74695923 | 7469592 | 8 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | FREQUENCY: OVER 30-90 MINUTES ON DAYS 1 AND 15. CYCLE= 28 DAYS. COURSE NO: 1 | U | 125085 | 561 | MG | SOLUTION FOR INFUSION | ||||||
| 74695923 | 7469592 | 9 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | FREQUENCY: OVER 30-90 MINUTES ON DAYS 1 AND 15. CYCLE= 28 DAYS. COURSE NO: 1 | U | 125085 | 1140 | MG | SOLUTION FOR INFUSION | ||||||
| 74695923 | 7469592 | 10 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | FREQUENCY: OVER 30-90 MINUTES ON DAYS 1 AND 15. CYCLE= 28 DAYS. COURSE NO: 1 | U | 125085 | 1140 | MG | SOLUTION FOR INFUSION | ||||||
| 74695923 | 7469592 | 11 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | FREQUENCY: OVER 30-90 MINUTES ON DAYS 1 AND 15. CYCLE= 28 DAYS. COURSE NO: 1 | U | 125085 | 1140 | MG | SOLUTION FOR INFUSION | ||||||
| 74695923 | 7469592 | 12 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | FREQUENCY: ON DAYS 1, 8, 15, 22. CYCLE=28 DAYS. FIRST COURSE. | U | 0 | 65 | MG | |||||||
| 74695923 | 7469592 | 13 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | ON DAYS 1,8,15,22. LAST DOSE PRIOR TO SAE: 26 APRIL 2010, COURSE 3 | U | 0 | 25 | MG | |||||||
| 74695923 | 7469592 | 14 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | FREQUENCY: ON DAYS 1, 8, 15, 22. CYCLE=28 DAYS. FIRST COURSE. | U | 0 | 30 | MG | |||||||
| 74695923 | 7469592 | 15 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | FREQUENCY: ON DAYS 1, 8, 15, 22. CYCLE=28 DAYS. FIRST COURSE. | U | 0 | 20 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 74695923 | 7469592 | 1 | Carcinoid tumour |
| 74695923 | 7469592 | 12 | Carcinoid tumour |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 74695923 | 7469592 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 74695923 | 7469592 | Blood bilirubin increased | |
| 74695923 | 7469592 | Hyperbilirubinaemia | |
| 74695923 | 7469592 | Platelet count decreased | |
| 74695923 | 7469592 | Upper gastrointestinal haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |